Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351
Raffaele Macarone Palmieri, Fabio Guolo, Luana Fianchi, Felicetto Ferrara et autres
CPX-351, a novel liposomal formulation of cytarabine and daunorubicin, represents the standard of care in fit patients with acute myeloid leukemia with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML). Considering its better safety profile than conventional intensive chemotherapy, we investigated its cost-to-benefit …
0 citations
IRIS Research product catalog (Sapienza University of Rome)